Coeptis Therapeutics Raises $10M to Accelerate AI-Driven Cell Therapy Innovations

Coeptis Therapeutics Holdings, Inc. (COEP), a biopharmaceutical company specializing in innovative cell therapy platforms, has successfully raised $10 million in a Series A Preferred financing round. Led by CJC Investment Trust, controlled by board member Christopher Calise, the funding will be used to strengthen the company's balance sheet, repay obligations, and support general corporate purposes. Notably, the capital will accelerate COEPTIS' integration of AI solutions and automation capabilities, particularly through their recently acquired NexGenAI Affiliates Network platform, aimed at enhancing research processes and operational efficiency in the biopharmaceutical sector.

The financing follows an initial closure of $4.3 million in June 2024. The Series A Preferred is convertible to common stock at $8.00 per share, with investors receiving a 15% equity stake in two newly formed subsidiaries: SNAP Biosciences and GEAR Therapeutics. The successful completion of COEPTIS' $10 million Series A Preferred financing represents a strategic milestone with multifaceted implications for investors. The $8.00 conversion price, positioned 22% below the current market value, suggests a balanced approach to capital raising while limiting immediate dilution. The unique structure, including a 15% equity stake in SNAP Biosciences and GEAR Therapeutics subsidiaries, effectively creates a 'double-play' opportunity for investors.

The participation of board member Christopher Calise's CJC Investment Trust as lead investor sends a powerful signal of insider confidence. This internal backing, combined with the premium conversion price relative to the current market cap of $21.7 million, indicates strong conviction in the company's fundamental value proposition. The debt reduction component is particularly significant given the current high-interest-rate environment. By strengthening the balance sheet and eliminating outstanding obligations, COEPTIS is positioning itself for improved financial flexibility and reduced carrying costs. The allocation towards AI integration, particularly through the NexGenAI platform, aligns with industry trends toward operational automation and efficiency optimization in the biotech sector.



The strategic emphasis on AI integration through the NexGenAI platform represents a sophisticated approach to addressing key operational challenges in the highly regulated biopharmaceutical sector. The focus on marketing and operational efficiencies through AI tools is particularly noteworthy, as it targets two critical cost centers in biotech development. The implementation of AI-driven tools in regulatory compliance and marketing optimization could provide significant competitive advantages. By automating complex compliance processes and enhancing marketing efficiency, COEPTIS is positioning itself to reduce operational overhead while potentially accelerating time-to-market for new therapeutics.



The creation of dedicated subsidiaries (SNAP Biosciences and GEAR Therapeutics) suggests a structured approach to technology integration, potentially allowing for more focused development of AI applications in specific therapeutic areas. This organizational structure could facilitate faster innovation cycles while maintaining regulatory compliance through specialized oversight. In conclusion, the successful completion of COEPTIS' $10 million Series A Preferred financing round signals a strategic milestone for the company, as it positions itself to accelerate AI-driven cell therapy innovations and enhance operational efficiency in the biopharmaceutical sector.